Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Assets (2016 - 2025)

Cytosorbents' Assets history spans 15 years, with the latest figure at $44.2 million for Q4 2025.

  • Quarterly results put Assets at $44.2 million for Q4 2025, down 6.73% from a year ago — trailing twelve months through Dec 2025 was $44.2 million (down 6.73% YoY), and the annual figure for FY2025 was $44.2 million, down 6.73%.
  • Assets for Q4 2025 was $44.2 million at Cytosorbents, down from $45.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $98.2 million in Q2 2021 to a low of $44.2 million in Q4 2025.
  • The 5-year median for Assets is $53.2 million (2023), against an average of $62.3 million.
  • The sharpest move saw Assets surged 99.34% in 2021, then tumbled 34.5% in 2022.
  • Year by year, Assets stood at $89.5 million in 2021, then fell by 29.37% to $63.2 million in 2022, then dropped by 16.25% to $53.0 million in 2023, then decreased by 10.55% to $47.4 million in 2024, then dropped by 6.73% to $44.2 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $44.2 million, $45.8 million, and $48.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.